Physician profile
John Andrew Rog
NPI 1073604518
$11,544.18
in general payments reported to CMS, 2019-2025
52 companies · $2,226 in 2025
The $2,226 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $699 · 2021: $1,800 · 2022: $1,975 · 2023: $2,523 · 2024: $2,180 · 2025: $2,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,928.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,451.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,239.19 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $1,104.17 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $1,068.96 | 2021-2025 | |
| Glaxosmithkline, LLC. | $872.23 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $645.15 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $553.38 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $534.48 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $412.29 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $410.77 | 2023-2025 | |
| Amgen INC. | $350.18 | 2019-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $207.72 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Biohaven Pharmaceutical Holding Company Ltd. | $192.78 | 2022 | |
| Esperion Therapeutics, INC. | $182.05 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.35 | 2020-2024 | Jardiance, Tradjenta, Synjardy |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $146.44 | 2020-2023 | |
| Dexcom, INC. | $121.61 | 2022-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $120.93 | 2023-2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $120.56 | 2022-2024 | Quviviq |
| Eisai INC. | $117.62 | 2020-2022 | |
| Allergan, INC. | $112.09 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.94 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $97.59 | 2021 | |
| Xeris Pharmaceuticals, INC. | $90.43 | 2023-2025 | Keveyis, Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $85.04 | 2022-2023 | Ingrezza |
| Amarin Pharma, INC. | $84.53 | 2021-2022 | |
| Shield Therapeutics INC | $78.90 | 2023-2025 | Accrufer |
| Hologic Sales and Service, LLC | $76.19 | 2023-2024 | Aptima, Thinprep 2000 Processor |
| Daiichi Sankyo INC. | $75.40 | 2021 | |
| Phadia US INC. | $58.62 | 2023-2024 | Immunocap |
| Genentech USA, INC. | $58.57 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $47.19 | 2021-2023 | |
| Ibsa Pharma INC. | $45.70 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $44.54 | 2021 | |
| Boston Scientific Corporation | $41.50 | 2023-2025 | General - Pain Management, Watchman Flx |
| Kowa Pharmaceuticals America, INC. | $40.92 | 2021-2024 | Zoryve |
| Vistapharm, INC. | $39.47 | 2021 | |
| Phathom Pharmaceuticals, INC. | $38.19 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $30.28 | 2024 | Eliquis |
| Arbor Pharmaceuticals, INC. | $26.76 | 2021 | |
| Scilex Pharmaceuticals INC. | $24.38 | 2023 | Ztlido |
| Ars Pharmaceuticals Operations, INC. | $23.95 | 2025 | Neffy |
| Medtronic, INC. | $23.90 | 2024 | Intellis Adaptivestim |
| Sanofi Pasteur INC. | $23.65 | 2023 | |
| Neuronetics, INC. | $22.61 | 2025 | Neurostar Tms Therapy System |
| Otsuka America Pharmaceutical, INC. | $20.09 | 2024 | Rexulti |
| Corcept Therapeutics | $19.39 | 2025 | Korlym |
| Sumitomo Pharma America, INC. | $19.12 | 2024 | Gemtesa |
| Almatica Pharma LLC | $18.14 | 2022 | |
| Si-Bone, INC. | $16.60 | 2023 | |
| Noven Therapeutics, LLC | $16.21 | 2025 | Xelstrym |
| Radiometer America, INC | $14.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rog listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.